Kingdon Capital Management’s Alpine Immune Sciences Inc ALPN Stock Holding History

Kingdon Capital Management’s Portfolio ALPN Stock Details ALPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-129,978	Closed	-$1.17M	–	148
2016 Q4	$1.17M	Sell	129,978 -5,447	-4%	-$109K	0.06%	115
2016 Q3	$4.4M	Hold	135,425	–	–	0.2%	88
2016 Q2	$2.49M	Buy	135,425 +71,287	+111%	+$1.27M	0.14%	88
2016 Q1	$1.07M	Sell	64,138 -35,778	-36%	-$716K	0.06%	102
2015 Q4	$3.09M	Sell	99,916 -4,810	-5%	-$164K	0.15%	94
2015 Q3	$5.43M	Buy	104,726 +23,476	+29%	+$1.54M	0.26%	79
2015 Q2	$4.92M	Buy	+81,250	New	+$4.84M	0.19%	98

Other funds holding ALPN

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Tiger Management New York $22.8M AUM 0.71% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SIM

Spark Investment Management New York $51.2M AUM 87.14% 1-Year Est. Return

PAM

Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

Kingdon Capital Management's ALPN Position: Q1 2017 in Review

Kingdon Capital Management sold out of Alpine Immune Sciences Inc (ALPN) in Q1 2017, closing a stake of 129,978 shares — an estimated $1.17M sold.

Kingdon Capital Management first reported a position in ALPN in Q2 2015 and held it in 7 quarters. The position peaked at $5.43M in Q3 2015. 28 funds tracked by Wall St. Rank hold ALPN as of Q1 2017.

Kingdon Capital Management reported no remaining Alpine Immune Sciences Inc position as of Q1 2017 after selling out during the quarter.
Kingdon Capital Management sold 129,978 Alpine Immune Sciences Inc shares in Q1 2017, an estimated $1.17M.
Kingdon Capital Management first reported a position in Alpine Immune Sciences Inc in Q2 2015 and held it in 7 quarters.
Kingdon Capital Management's Alpine Immune Sciences Inc position peaked at $5.43M in Q3 2015.
28 funds tracked by Wall St. Rank held Alpine Immune Sciences Inc as of Q1 2017.

Based on Kingdon Capital Management's 13F filing for Q1 2017, filed 15 May 2017.